Healthcare / Health Information ServicesOslo
$3.49
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-69.7M · quality 50.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$50M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-51.9%
↓Gross Margin
67.1%
↑Debt/Equity
0.12
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-62.1%
FCF CAGR
—
FCF margin
-124.1%
FCF / Net income
0.89x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $10.7M · net income $-14.9M · FCF $-13.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $10.7M | $10.7M | $249388.00 | $59.2M | $195.0M |
| Net Income | $-14.9M | $-14.9M | $-150.9M | $30.0M | $-154.6M |
| EBITDA | $-12.1M | $-12.1M | $-71.2M | $91.2M | $-20.3M |
| EPS | -1.21 | -1.21 | -22.07 | 7.55 | -38.87 |
| Gross Margin | 67.1% | 67.1% | -646.8% | 85.2% | 83.4% |
| Operating Margin | -149.2% | -149.2% | -54633.7% | -188.6% | -76.5% |
| Net Margin | -139.6% | -139.6% | -60501.9% | 50.8% | -79.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.12 | 0.12 | — | — | 0.36 |
| Current Ratio | 1.37 | 1.37 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-13.2M | $-13.2M | $-69.7M | $-96.6M | $-190.3M |
| Returns | |||||
| ROE | -51.9% | -51.9% | -842.6% | 22.5% | -25.8% |
| Valuation | |||||
| P/E | — | — | — | 3.00 | — |
| EV/EBITDA | — | — | — | 0.37 | — |
| P/B | 1.76 | 1.76 | 1.13 | 0.67 | 0.53 |
| Growth & Yield | |||||
| Revenue Growth | 4173.0% | 4173.0% | -99.6% | -69.7% | — |
| EPS Growth | 94.5% | 94.5% | -392.2% | 119.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+8.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-22.07 → -1.21
Residual
+8.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.